To evaluate de novo host antitumor responses toward non-AFP antigens, we employed the ovalbumin (OVA)-expressing HCC model to directly assess the contribution of host immunity by detecting anti-OVA immune responses [28]. The gene discussed is AFP; the disease is hepatocellular carcinoma.